Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS: +63.2%
Free cash flow: −112.8%

Quarter to June 2026, against a year earlier

Insider buying

15.85 1.66 +11.70%

Follow SMMT

Alert me

Market cap: $11.3B
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 3/9
Altman Z: 0.88
Beneish M: −5.00
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Summit Therapeutics PLC (SMMT) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Summit Therapeutics PLC (SMMT) trades at a P/S ratio of 15,884×. Over the past ten years it has ranged from 0.0× (July 2017) to 38,422× (April 2025); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SMMT/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Summit Therapeutics PLC P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SMMT/metrics/ps-ratio">Summit Therapeutics PLC (SMMT) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2022	1,371×	600.08%
FY2021	196×	(48.45%)
FY2020	380×	309.06%
FY2019	92.9×	45,996.72%
FY2019	0.2×	(64.72%)
FY2018	0.6×	(98.12%)
FY2018	30.4×	(36.56%)
FY2017	48.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/S ratio	Change
Dec 2022	1,371×	427.29%
Sep 2022	260×	279.54%
Jun 2022	68.5×	(62.72%)
Mar 2022	184×	(6.17%)
23 more quarters	Free account

Against its own ten years

Low 0.0× High 38,422×

Ten-year median 205×

Current reading's percentile 79

Company	P/S ratio
PCVX Vaxcyte, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	3.0×
JAZZ Jazz Pharmaceuticals PLC compare	3.1×
HALO Halozyme Therapeutics, Inc. compare	7.8×
TECH Bio-Techne Corp compare	9.3×
ASND Ascendis Pharma A/S compare	13.5×
BBIO BridgeBio Pharma, Inc. compare	15.5×
KYMR Kymera Therapeutics, Inc. compare	120×
SMMT Summit Therapeutics PLC	15,884×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Summit Therapeutics PLC (SMMT) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on SMMT

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on SMMT

Stockrow Weekly